M&G Investments spearheads $50M funding round for bit.bio

M&G Investments leads a $50 million Series C funding for bit.bio, a biotech firm focusing on human cell programming technology. The investment will fuel bit.bio's product development, global expansion, toxicology market entry, and AI model training. Lord David Prior joins bit.bio as an independent director and new Board Chair.